



Ref: FOIA Reference 2023/24-315

Date: 29<sup>th</sup> August 2023

Email [foi@uhnm.nhs.uk](mailto:foi@uhnm.nhs.uk)

Dear

I am writing to acknowledge receipt of your email dated 18th August 2023 requesting information under the Freedom of Information Act (2000) regarding dermatological conditions.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore, the response below is for the two sites combined from that date where appropriate.

**Q1 I am analysing the treatment of dermatological conditions in the UK. Could you please answer the following questions.**

**Q1. How many patients were treated in the last 4 months (April to July 2023) by the dermatology department with each of the following products:**

- **Abrocitinib**
- **Acitretin**
- **Alitretinoin**
- **Azathioprine**
- **Baricitinib**
- **Ciclosporin**
- **Dupilumab**
- **Methotrexate**
- **Mycophenolate mofetil**
- **Pimecrolimus**
- **Phototherapy (UVB or PUVA)**
- **Tacrolimus ointment**
- **Tralokinumab**
- **Upadacitinib**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the

terms of Section 40(2) of the FOI Act. *Personal information*. However, as the Trust is committed to openness and transparency, we can band the numbers as being <5  
*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- Abrocitinib - 0
- Acitretin -79
- Alitretinoin - 0
- Azathioprine - 9
- Baricitinib - 5
- Ciclosporin - 43
- Dupilumab - 60
- Methotrexate - 137
- Mycophenolate mofetil - 8
- Pimecrolimus - <5
- Phototherapy (UVB or PUVA) - 0
- Tacrolimus ointment -26
- Tralokinumab -<5
- Upadacitinib -<5

**Q2 Q2. How many patients were treated by the dermatology department in the previous 4-month period (December 22 - March 23) with Dupixent?**

A2 Fifty-six (56)

**Q3 Q3. For patients treated by the dermatology department with Dupilumab in the four months from December 22 to March 2023, could you please tell us:**

- a. How many patients were treated in the subsequent 4-month period (April - July 23) with Dupilumab?**
- b. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies - Abrocitinib, Baricitinib, Tralokinumab and Upadacitinib?**
- c. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following immunosuppressants - Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?**
- d. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following - Acitretin, Alitretinoin, Pimecrolimus or Tacrolimus?**

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However, as the Trust is committed to openness and transparency, we can band the numbers as being <5  
*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:*

- a. 52
- b. <5
- c. 0

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



**Rachel Montinaro**

Data Security and Protection Manager - Records